Skip to main content
CDIO
NASDAQ Life Sciences

Cardio Diagnostics Posts $1.73M Q3 Loss; Cash at $3.94M as Material Weakness and Nasdaq MVLS Risk Persist

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.675
Mkt Cap
$4.957M
52W Low
$0.97
52W High
$7.91
52W Position info
73% above low
Off High info
79% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CDIO sits 73% above its 52-week low of $0.97.

Summary

Cardio Diagnostics posted a $1.73M Q3 loss on $3,590 of revenue, with cash down to $3.94M and continued reliance on its ATM. The filing reaffirms a material weakness in controls and warns that a new Nasdaq $5M MVLS rule, currently stayed, could trigger delisting.


Key Events · Earnings and Guidance · CDIO

  • Q3 Loss Widens Slightly

    Net loss for Q3 2026 was $1,732,331, compared with $1,714,536 a year earlier, on revenue of just $3,590.

  • Cash Burn Continues

    Cash fell to $3,942,882 at September 30, 2026 from $5,110,630 at December 31, 2025, with operating cash use of $4,420,474 over the nine months.

  • ATM Funds Operations

    During the nine months, the company sold 1,133,418 shares under its ATM for gross proceeds of $3,788,175, and it may sell up to another $5,298,889.

  • Material Weakness Reaffirmed

    Management again identified inadequate segregation of duties as a material weakness in internal control over financial reporting as of September 30, 2026.


Analysis · CDIO · Life Sciences

Cash burn remains the central story for this pre-revenue diagnostics company. Q3 2026 net loss came in at $1,732,331 on just $3,590 of revenue, bringing the nine-month loss to $5,021,957. Cash stood at $3,942,882, down from $5,110,630 at year-end 2025, and management says it will rely primarily on its ATM to fund operations. The filing also reaffirms a material weakness in internal controls tied to inadequate segregation of duties. Separately, a new Nasdaq rule requiring $5 million in market value of listed securities—adopted July 22, 2026 and temporarily stayed by the SEC on July 29, 2026—could lead to delisting with no cure period. For a company already dependent on equity sales to survive, that would make raising capital far harder.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CDIO was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.97 to $7.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CDIO - Latest Insights

CDIO
Aug 07, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.79
Real-time Price: $1.60 info
Change: -$0.190 (-11%) info
Market Cap: $4.735M info
CDIO
Jul 13, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $1.60 info
Change: -$0.190 (-11%) info
Market Cap: $4.735M info
CDIO
Jun 24, 2026, 1:36 PM EDT
Source: FinanceWire
Importance Score:
7
Price at Filing: $2.04
Real-time Price: $1.60 info
Change: -$0.440 (-22%) info
Market Cap: $4.735M info
CDIO
May 15, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.55
Real-time Price: $1.60 info
Change: +$0.050 (+3%) info
Market Cap: $4.735M info
CDIO
May 15, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.55
Real-time Price: $1.60 info
Change: +$0.050 (+3%) info
Market Cap: $4.735M info